Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel

Abstract This study aimed to compare second-line treatment outcomes for patients with unresectable pancreatic cancer previously treated with gemcitabine plus nab–paclitaxel (GnP) therapy. We conducted an integrated analysis of two retrospective studies included 318 patients receiving nanoliposomal i...

Full description

Bibliographic Details
Published in:	Scientific Reports
Main Authors:	Taro Shibuki, Taiga Otsuka, Mototsugu Shimokawa, Junichi Nakazawa, Shiho Arima, Masaru Fukahori, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Akitaka Makiyama, Hozumi Shimokawa, Shigeyuki Takeshita, Kazuo Nishikawa, Azusa Komori, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Takuya Honda, Hiroki Taguchi, Kengo Tsuneyoshi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-07-01
Subjects:	Pancreatic cancer Second line Nanoliposomal irinotecan S-1 FOLFIRINOX
Online Access:	https://doi.org/10.1038/s41598-024-65689-8

Similar Items

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
by: Masaru Fukahori, et al.
Published: (2023-11-01)

Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)
by: Taro Shibuki, et al.
Published: (2022-01-01)

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
by: Tsuyoshi Shirakawa, et al.
Published: (2023-05-01)

Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
by: Tsuyoshi Shirakawa, et al.
Published: (2024-03-01)

Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer
by: Keisuke Miwa, et al.
Published: (2025-07-01)

Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
by: Adam R. Wolfe, et al.
Published: (2020-07-01)

A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer
by: Tomoko Kodama, et al.
Published: (2024-05-01)

Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer
by: Lenka N.C. Boyd, et al.
Published: (2024-09-01)

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
by: Masashi Sawada, et al.
Published: (2020-05-01)

Second-line Modified GTX versus Gemcitabine-Nab-Paclitaxel (GmAb) Following First-Line FOLFIRINOX in Advanced Pancreatic Cancer: A Retrospective Analysis at the American University of Beirut Medical Center (AUBMC)
by: Sally Temraz, et al.
Published: (2023-10-01)

Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution
by: Qi Quan, et al.
Published: (2020-12-01)

FOLFIRINOX for advanced pancreatic adenocarcinoma in Brazil: a single-institution experience
by: José Mauricio Mota, et al.
Published: (2018-01-01)

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis
by: Beilei Zhang, et al.
Published: (2021-06-01)

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients
by: Konstantin Schlick, et al.
Published: (2021-02-01)

Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study
by: Lu Zou, et al.
Published: (2021-07-01)

Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient
by: Anne Katrin Berger, et al.
Published: (2017-12-01)

Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer
by: Joshua K. Kays, et al.
Published: (2018-08-01)

Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
by: Young Hoon Choi, et al.
Published: (2021-03-01)

Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study
by: Jung Hoon Kim, et al.
Published: (2018-06-01)

Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)
by: Elisa Giommoni, et al.
Published: (2021-05-01)

改良FOLFIRINOX方案一线治疗晚期转移性胰腺癌
by: 农天文, et al.
Published: (2018-01-01)

Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use
by: Joanna Gotfrit, et al.
Published: (2025-02-01)

A resected case of acinar cell carcinoma of the pancreas with liver metastasis following chemotherapy using modified FOLFIRINOX
by: Shuhei Yamada, et al.
Published: (2023-08-01)

Efficacy and Safety of Different Sequences for mFOLFIRINOX (or SOXIRI) and Gemcitabine Plus Albumin-Bound Paclitaxel in Unresectable Pancreatic Cancer
by: Huang S, et al.
Published: (2025-10-01)

Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial
by: Christelle Bouchart, et al.
Published: (2023-09-01)

A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer
by: Ayhan Ulusakarya, et al.
Published: (2020-06-01)

[Comment] Brazil-TNT : a randomized phase 2 trial of neoadjuvant chemoradiation followed by FOLFIRINOX versus chemoradiation for stage Ⅱ/Ⅲ rectal cancer
by: Li Laiyuan, et al.
Published: (2024-08-01)

Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer
by: Ji Hye Min, et al.
Published: (2025-02-01)

Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer
by: Manoj Amrutkar, et al.
Published: (2025-02-01)

Differences in collagen structure and organization in primary and metastatic pancreatic cancer and the effects of FOLFIRINOX treatment
by: Caroline Seilstad, et al.
Published: (2026-06-01)

Development of transcriptomic tools for predicting the response to individual drug of the mFOLFIRINOX regimen in patients with metastatic pancreatic cancer
by: Nicolas Fraunhoffer, et al.
Published: (2024-09-01)

Pre-treatment inflamed tumor immune microenvironment is associated with FOLFIRINOX response in pancreatic cancer
by: Zachary Gao, et al.
Published: (2023-11-01)

Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy
by: Kangpyo Kim, et al.
Published: (2024-03-01)

Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer
by: Zainab Hussain, et al.
Published: (2024-01-01)

A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy
by: Casper W.F. van Eijck, et al.
Published: (2024-03-01)

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
by: Q. P. Janssen, et al.
Published: (2021-03-01)

Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2)
by: T. Shirakawa, et al.
Published: (2025-06-01)

Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302)
by: Tomonori Araki, et al.
Published: (2025-02-01)

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial
by: J. L. van Dam, et al.
Published: (2023-08-01)

Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab‐paclitaxel plus gemcitabine as second or later‐line treatment
by: Guido Giordano, et al.
Published: (2024-06-01)